Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRXL2CP1 refers to a putative pseudogene related to the PRXL2C gene. Pseudogenes are typically noncoding DNA sequences that resemble genes but lack protein-coding ability, often due to mutations or deletions. Some pseudogenes may have regulatory or non-coding RNA functions, though this is generally rare and not established for PRXL2CP1[3]. There is no evidence that PRXL2CP1 has biological activity, therapeutic relevance, chemical interactions, or validated disease associations. The canonical protein-coding gene in this family is PRXL2C (Peroxiredoxin Like 2C), which has some reported regulatory roles in ERK1/2 and AKT1 signaling and a connection to Fanconi anemia, but this does not extend to PRXL2CP1[1]. The entry appears incorrect for structured target data, and no alternate common aliases, mechanisms, or pharmacological details exist for PRXL2CP1. If you are seeking molecule/receptor information for a therapeutic target, PRXL2CP1 does not qualify under any classification commonly used in drug discovery or molecular biology. If another target is intended, consider verifying the name or consulting experimental databases for more detailed annotation[1][3].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRXL2C pseudogene 1 (PRXL2CP1).